StreetInsider.com News Articles

Form 6-K Clinuvel Pharmaceuticals For: Aug 27

Thu, 27 Aug 2026 11:37:00 -0400

si-local-file:///var/storage/secattach/20260827/26987572.html

Form 6-K Clinuvel Pharmaceuticals For: Aug 27

Thu, 27 Aug 2026 11:37:00 -0400

si-local-file:///var/storage/secattach/20260827/26987572.html

Form 6-K Clinuvel Pharmaceuticals For: Aug 27

Thu, 27 Aug 2026 11:37:00 -0400

si-local-file:///var/storage/secattach/20260827/26987572.html

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Thu, 27 Aug 2026 01:42:00 -0400

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.

“This position provides us with

Form 6-K Clinuvel Pharmaceuticals For: Aug 20

Thu, 20 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260820/26952380.html

Form 6-K Clinuvel Pharmaceuticals For: Aug 20

Thu, 20 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260820/26952380.html

Form 6-K Clinuvel Pharmaceuticals For: Aug 20

Thu, 20 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260820/26952380.html

Form 6-K Clinuvel Pharmaceuticals For: Aug 12

Wed, 12 Aug 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260812/26908343.html

Form 6-K Clinuvel Pharmaceuticals For: Aug 12

Wed, 12 Aug 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260812/26908343.html

Form 6-K Clinuvel Pharmaceuticals For: Aug 12

Wed, 12 Aug 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260812/26908343.html

Form 6-K Clinuvel Pharmaceuticals For: Jul 30

Thu, 30 Jul 2026 06:10:00 -0400
si-local-file:///var/storage/secattach/20260730/26837995.html

Form 6-K Clinuvel Pharmaceuticals For: Jul 30

Thu, 30 Jul 2026 06:10:00 -0400
si-local-file:///var/storage/secattach/20260730/26837995.html

Form 6-K Clinuvel Pharmaceuticals For: Jul 30

Thu, 30 Jul 2026 06:10:00 -0400
si-local-file:///var/storage/secattach/20260730/26837995.html

Form 6-K Clinuvel Pharmaceuticals For: Jul 28

Tue, 28 Jul 2026 06:06:00 -0400
si-local-file:///var/storage/secattach/20260728/26821738.html